NEW YORK (GenomeWeb) – Enigma Diagnostics today said that it will collaborate with China’s National Institute for Communicable Disease Control and Prevention on the development of rapid molecular diagnostics for infectious disease pathogens.
The assays will be developed for us on Enigma's Mini Laboratory system, a real-time PCR-based, point-of-care molecular diagnostics platform, which the Porton Down, UK-based firm said "enables testing for the widest range of DNA and RNA disease targets with a fast turnaround time." The partners didn't specify which pathogens they will target, and they didn't provide terms of their agreement.
"This is a milestone agreement for Enigma which recognises the unique benefits and relevance of the Enigma ML system for global point-of-care testing and strategic healthcare planning," Enigma Chairman John McKinley said in a statement. "The collaboration is a cornerstone achievement in our China strategy and our broader commercialisation programme and follows on from the European CE mark registration of the Enigma ML system in January this year."
Enigma received the CE Mark and launched the ML along with a combined test for influenza A/B and respiratory syncytial virus in January.
The ICDC is part of the China Center for Disease Control and Prevention, an organization focused on infectious disease prevention and control.